FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591497357> ?p ?o ?g. }

• W2591497357 endingPage "e15019" @default.
• W2591497357 startingPage "e15019" @default.
• W2591497357 abstract "e15019 Background: PSA decline ≥30% and ≥50% within 90 days of starting chemotherapy are suboptimal surrogates for overall survival (OS) and only capture a proportion of total benefit. Changes in ALP were shown to complement PSA changes as prognostic factors for overall survival [OS] in men treated with chemotherapy in the TAX327 trial dataset. This analysis was performed to independently validate these findings in a different dataset. Methods: 221 men recruited to a randomized phase II trial of DP+AT-101 (bcl-2 inhibitor) versus DP+placebo were studied. No significant differences in outcomes were observed; hence, both arms were combined for analysis. Changes in ALP and PSA prior to day 90 were measured and evaluated for prognostic ability to predict OS from day 90 using the Kaplan-Meir method and Cox proportional hazards regression. For inclusion, patients were required to have bony metastases at baseline, ALP ≥120 u/L and survival beyond day 90. ALP normalization was defined as an ALP of <120 and PSA response was defined as decline ≥30% from baseline within 90 days of randomization. Results: 100 men were eligible for analysis h ALP≥120 and 45 had normalization of ALP by day 90. OS from day 90 was significantly improved (HR: 0.38, 95% CI: 0.21-0.68) among those with normalization (1-year OS: 71.5%, 95% CI: 55.3-82.7) compared with those not having normalization (47.3%, 95% CI: 33.1-60.2). ALP normalization was independent of PSA response as a prognostic factor. 1-year OS for men with ALP normalization and with/without PSA-response was 76.9% / 62.5%, and for men without ALP normalization and with/without PSA-response was 56.6% / 30.0%. 29 men had increased ALP at day 90 from baseline and these men had significantly worse survival (9.7 months vs. 17.4 months) even after adjusting for PSA progression (hazard ratio:2.43; 95% CI: 1.48-4.00). Conclusions: ALP changes on DP based therapy complement PSA changes as prognostic factors associated with OS. Although not a surrogate for OS, ALP changes may be useful in estimating prognosis and facilitating treatment decisions in the setting of PSA flare or lack of PSA response to docetaxel." @default.
• W2591497357 created "2017-03-03" @default.
• W2591497357 creator A5021879267 @default.
• W2591497357 creator A5038489185 @default.
• W2591497357 creator A5052069729 @default.
• W2591497357 creator A5061916244 @default.
• W2591497357 creator A5075558949 @default.
• W2591497357 creator A5081246052 @default.
• W2591497357 creator A5084120344 @default.
• W2591497357 creator A5085662370 @default.
• W2591497357 creator A5087929642 @default.
• W2591497357 creator A5089150094 @default.
• W2591497357 date "2011-05-20" @default.
• W2591497357 modified "2023-09-27" @default.
• W2591497357 title "Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)." @default.
• W2591497357 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e15019" @default.
• W2591497357 hasPublicationYear "2011" @default.
• W2591497357 type Work @default.
• W2591497357 sameAs 2591497357 @default.
• W2591497357 citedByCount "0" @default.
• W2591497357 crossrefType "journal-article" @default.
• W2591497357 hasAuthorship W2591497357A5021879267 @default.
• W2591497357 hasAuthorship W2591497357A5038489185 @default.
• W2591497357 hasAuthorship W2591497357A5052069729 @default.
• W2591497357 hasAuthorship W2591497357A5061916244 @default.
• W2591497357 hasAuthorship W2591497357A5075558949 @default.
• W2591497357 hasAuthorship W2591497357A5081246052 @default.
• W2591497357 hasAuthorship W2591497357A5084120344 @default.
• W2591497357 hasAuthorship W2591497357A5085662370 @default.
• W2591497357 hasAuthorship W2591497357A5087929642 @default.
• W2591497357 hasAuthorship W2591497357A5089150094 @default.
• W2591497357 hasConcept C121608353 @default.
• W2591497357 hasConcept C126322002 @default.
• W2591497357 hasConcept C126894567 @default.
• W2591497357 hasConcept C142724271 @default.
• W2591497357 hasConcept C143998085 @default.
• W2591497357 hasConcept C160160445 @default.
• W2591497357 hasConcept C181199279 @default.
• W2591497357 hasConcept C185592680 @default.
• W2591497357 hasConcept C204243189 @default.
• W2591497357 hasConcept C204787440 @default.
• W2591497357 hasConcept C207103383 @default.
• W2591497357 hasConcept C27081682 @default.
• W2591497357 hasConcept C2775832370 @default.
• W2591497357 hasConcept C2776694085 @default.
• W2591497357 hasConcept C2777899217 @default.
• W2591497357 hasConcept C2778720950 @default.
• W2591497357 hasConcept C2780192828 @default.
• W2591497357 hasConcept C2781190966 @default.
• W2591497357 hasConcept C44249647 @default.
• W2591497357 hasConcept C50382708 @default.
• W2591497357 hasConcept C535046627 @default.
• W2591497357 hasConcept C55493867 @default.
• W2591497357 hasConcept C71924100 @default.
• W2591497357 hasConceptScore W2591497357C121608353 @default.
• W2591497357 hasConceptScore W2591497357C126322002 @default.
• W2591497357 hasConceptScore W2591497357C126894567 @default.
• W2591497357 hasConceptScore W2591497357C142724271 @default.
• W2591497357 hasConceptScore W2591497357C143998085 @default.
• W2591497357 hasConceptScore W2591497357C160160445 @default.
• W2591497357 hasConceptScore W2591497357C181199279 @default.
• W2591497357 hasConceptScore W2591497357C185592680 @default.
• W2591497357 hasConceptScore W2591497357C204243189 @default.
• W2591497357 hasConceptScore W2591497357C204787440 @default.
• W2591497357 hasConceptScore W2591497357C207103383 @default.
• W2591497357 hasConceptScore W2591497357C27081682 @default.
• W2591497357 hasConceptScore W2591497357C2775832370 @default.
• W2591497357 hasConceptScore W2591497357C2776694085 @default.
• W2591497357 hasConceptScore W2591497357C2777899217 @default.
• W2591497357 hasConceptScore W2591497357C2778720950 @default.
• W2591497357 hasConceptScore W2591497357C2780192828 @default.
• W2591497357 hasConceptScore W2591497357C2781190966 @default.
• W2591497357 hasConceptScore W2591497357C44249647 @default.
• W2591497357 hasConceptScore W2591497357C50382708 @default.
• W2591497357 hasConceptScore W2591497357C535046627 @default.
• W2591497357 hasConceptScore W2591497357C55493867 @default.
• W2591497357 hasConceptScore W2591497357C71924100 @default.
• W2591497357 hasIssue "15_suppl" @default.
• W2591497357 hasLocation W25914973571 @default.
• W2591497357 hasOpenAccess W2591497357 @default.
• W2591497357 hasPrimaryLocation W25914973571 @default.
• W2591497357 hasRelatedWork W2158933186 @default.
• W2591497357 hasRelatedWork W2568045406 @default.
• W2591497357 hasRelatedWork W2589688070 @default.
• W2591497357 hasRelatedWork W2591232777 @default.
• W2591497357 hasRelatedWork W2776594178 @default.
• W2591497357 hasRelatedWork W2912565296 @default.
• W2591497357 hasRelatedWork W2921078229 @default.
• W2591497357 hasRelatedWork W2931451269 @default.
• W2591497357 hasRelatedWork W3011636404 @default.
• W2591497357 hasRelatedWork W4206312281 @default.
• W2591497357 hasVolume "29" @default.
• W2591497357 isParatext "false" @default.
• W2591497357 isRetracted "false" @default.
• W2591497357 magId "2591497357" @default.
• W2591497357 workType "article" @default.